Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Therapy with the oral antidiabetic agent troglitazone (Rezulin) has been associated with cases of severe hepatotoxicity and drug-induced liver failure, which led to the recent withdrawal of the product from the U.S. market. While the mechanism of this toxicity remains unknown, it is possible that chemically reactive metabolites of the drug play a causative role. In an effort to address this possibility, this study was undertaken to determine whether troglitazone undergoes metabolism in human liver microsomal preparations to electrophilic intermediates. Following incubation of troglitazone with human liver microsomes and with cDNA-expressed cytochrome P450 isoforms in the presence of glutathione (GSH), a total of five GSH conjugates (M1-M5) were detected and identified tentatively by LC-MS/MS analysis. In two cases (M1 and M5), the structures of the adducts were confirmed by NMR spectroscopy and/or by comparison with an authentic standard prepared by synthesis. The formation of GSH conjugates M1-M5 revealed the operation of two distinct metabolic activation pathways for troglitazone, one of which involves oxidation of the substituted chromane ring system to a reactive o-quinone methide derivative, while the second involves a novel oxidative cleavage of the thiazolidinedione (TZD) ring, potentially generating highly electrophilic alpha-ketoisocyanate and sulfenic acid intermediates. When troglitazone was administered orally to a rat, samples of bile were found to contain GSH conjugates which reflected the operation of these same metabolic pathways in vivo. The finding that metabolism of the TZD ring of troglitazone was catalyzed selectively by P450 3A enzymes is significant in light of the recent report that troglitazone is an inducer of this isoform in human hepatocytes. The implications of these results are discussed in the context of the potential for troglitazone to covalently modify hepatic proteins and to cause oxidative stress through redox cycling processes, either of which may play a role in drug-induced liver injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mechanistic studies subsequently identified bioactivation by CYP3A4 and CYP2C8 to reactive quinone-like metabolites and ring-opened sulfenic acid intermediates that covalently bind cellular macromolecules and trigger mitochondrial injury, neither of which was reliably flagged by standard preclinical hepatotoxicity assays [75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Fialuridine (Section 7.1) and troglitazone (Section 7.4) are intrinsic toxicodynamic failures, driven by human-relevant mitochondrial injury and reactive-metabolite formation, respectively.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Troglitazone, the first marketed thiazolidinedione, was withdrawn after reports of severe idiosyncratic hepatotoxicity, including fulminant liver failure and transplantation.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
In the citing paper
“Fourth, idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [76]
Citations
Cites
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 230
Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., & Horikoshi, H. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00122a022 · Cited by 221
Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., & Bonkovsky, H. L. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01707.x · Cited by 209
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Kassahun, K., Hu, P. L., Grillo, M. P., Davis, M. R., Jin, L., & Baillie, T. A. (1994) · Chemico-Biological Interactions · doi:10.1016/0009-2797(94)90014-0 · Cited by 74
Self-citationOhe, T., Mashino, T., & Hirobe, M. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1185 · Cited by 64
Davis, M. R., Kassahun, K., Jochheim, C. M., Brandt, K. M., & Baillie, T. A. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00033a020 · Cited by 44
Self-citation
Research works printed but not linked: 16
- Henry R. R., 1997, Thiazolidinones. Curr. Ther. Diabetes 26, 553−573
- Hu J., 1999, J. Org. Chem., 64
- Hart T. W., 1985, Tetrahedron Lett., 26
- Baillie T. A., 1993, Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319−325
- Kassahun K., 1997, Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: Identification of Phase I metabolites and glutathione conjugates. Chem. Res. Toxicol. 10, 1228−1233
- Borel A. G., 1993, Identification of carbomoylated thiol conjugates as metabolites of the antineoplastic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, in rats and humans. Drug Metab. Dispos. 21, 889−901
- Kawai K., 1997, Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim.-Forsch. 47, 356−368
- Loi C. M., 1997, J. Clin. Pharmacol., 37
- Ohe T., 1997, Substituent elimination from p-substituted phenols by cytochrome P450. ipso-Substitution by the oxygen atom of the active species. Drug Metab. Dispos. 25, 116−122
- Ohe T., 2000, Novel metabolic pathway of estrone and 17β-estradiol catalyzed by cytochrome P-450. Drug Metab. Dispos. 28, 110−112
- Yamazaki H., 1999, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260−1266
- He K., 1999, Proceedings of the 9th North American ISSX Meeting, #207
- Polsker G. L., 1999, Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 57, 409−438
- Ramachandran V., 1999, Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 27, 1194−1199
- Mansuy D., 1991, J. Am. Chem. Soc., 113
- Abbreviations TZD, thiazolidinedione
Cited by
Items 201–300 of 316
Yamazaki, H., Kuribayashi, S., Inoue, T., Honda, T., Tateno, C., Oofusa, K., Ninomiya, S., Ikeda, T., Izumi, T., & Horie, T. (2014) · Toxicology Research · doi:10.1039/c4tx00068d · Cited by 13
Frederick, D. M., Jacinto, E. Y., Patel, N. N., Rushmore, T. H., Tchao, R., & Harvison, P. J. (2011) · Toxicology in Vitro · doi:10.1016/j.tiv.2011.09.015 · Cited by 13
“In analogy to the glitazones (Kassahun et al., 2001; Tettey et al., 2001; Alvarez-Sánchez et al., 2006), CYP3A4-mediated metabolic activation of DCPT could conceivably occur via a sulfoxidation step (Fig.”
BackgroundMethodInfluentialKeil, A. M., Frederick, D. M., Jacinto, E. Y., Kennedy, E. L., Zauhar, R. J., West, N. M., Tchao, R., & Harvison, P. J. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.07.015 · Cited by 13
“The other N-phenyl analogues, DCPO and NDPS, were available from previous work in our laboratory (Kennedy et al., 2003).”
BackgroundMethodInfluentialAgrawal, A. K., Hop, C. E. C. A., Pang, J., Elipe, M. V. S., Desai, R. C., Leung, K., & Franklin, R. B. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2004.10.036 · Cited by 12
Self-citationEnantiomer ratio of MK‐0767 in humans and nonclinical species
Shen, Z., Bakhtiar, R., Komuro, M., Awano, K., Taga, F., Colletti, A. E., Hora, D. F., Feeney, W. P., Iliff, S. A., Franklin, R. B., et al. (2005) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1897 · Cited by 11
Mezine, I., Bode, C., Raughley, B., Bhoopathy, S., Roberts, K. J., Owen, A. J., & Hidalgo, I. J. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.05.011 · Cited by 11
Fragmentation of Drugs and Pesticides
Niessen, W. M. A., & C., R. A. C. (2017) · Wiley eBooks · doi:10.1002/9781119294269.ch4 · Cited by 11
Wei, H., & Li, A. P. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000645 · Cited by 10
“…with previous findings of its metabolic activation to reactive metabolites involving the sulfur moiety of thiazolidinedione nucleus firstly reported by Kassahun et al. (Kassahun et al., 2001) and subsequently confirmed by others (Prabhu et al., 2002; Saha et al., 2010; Okada et al., 2011).”
BackgroundResultTing, H.-H., Chiou, Y., Chang, T.-Y., Lin, G.-Y., Li, P., & Shih, C. (2023) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3451 · Cited by 10
“The ring opening in thiazolidinedione has been linked to reactive metabolites of thiazolidinedione drugs [21].”
CHEMICAL MECHANISMS OF TOXICITY: BASIC KNOWLEDGE FOR DESIGNING SAFER DRUGS
Macherey, A., & Dansette, P. M. (2003) · Elsevier eBooks · doi:10.1016/b978-012744481-9/50036-2 · Cited by 11
Crincoli, C. M., Patel, N. N., Tchao, R., & Harvison, P. J. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.006 · Cited by 10
Yenes, S., Commandeur, J. N. M., Vermeulen, N. P. E., & Messeguer, Á. (2004) · Chemical Research in Toxicology · doi:10.1021/tx030036f · Cited by 10
Uchiyama, M., Iwabuchi, H., Tsuruta, F., Abe, K., Makoto, T., Koda, H., Oguchi, M., Okazaki, O., & Izumi, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036194 · Cited by 10
“…drugs, such as rosiglitazone (Bolton et al., 1996; Baldwin et al., 1999; Cox et al., 2000; Hop et al., 2002) and pioglitazone (Krieter et al., 1994; Kiyota et al., 1997; Maeshiba et al., 1997; Shen et al., 2003), have been reported to be the oxidation, glucuronidation, or sulfation of the other…”
BackgroundŁuczak, E., Wieczfińska, J., Sokołowska, M., Pniewska, E., Luczynska, D., & Pawliczak, R. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.006 · Cited by 9
Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors
Boelsterli, U. A., & Kashimshetty, R. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01015-0 · Cited by 11
de Campos, M. L., Cerqueira, L. B., Silva, B. C. U., Franchin, T. B., Pitta, M. G. D. R., Pitta, I. R., Peccinini, R. G., & Pontarolo, R. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079012 · Cited by 9
“Considering TZDs, it was proposed that the ring opening may be related to the formation of reactive metabolites of troglitazone (Kassahun et al., 2001).”
BackgroundMitochondrial Dysfunction in Drug‐Induced Liver Injury
Borgne‐Sanchez, A., & Fromenty, B. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch5 · Cited by 10
Cytochrome P450 Activation of Toxins and Hepatotoxicity
Guengerich, F. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00002-9 · Cited by 13
Padilha, E. C., Wang, J., Kerns, E., Lee, A. M., Huang, W., Jiang, J., McKew, J. C., Mutlib, A. E., Peccinini, R. G., Yu, P. B., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00234 · Cited by 8
Ontology-based knowledge management of troglitazone-induced hepatotoxicity
Hug, H., Dannecker, R., Schindler, R., Bagatto, D., Stephan, A., Wess, R. A., & Gut, J. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03252-0 · Cited by 8
“Allelic variants of the genes coding for the cytochrome P450 isoenzymes CYP3A4, CYP2C8, CYP2C9 and CYP2C19 involved in the oxidation of troglitazone to troglitazone metabolite 3 [ 19 ,20] and allelic variants of the gene coding for the canalicular bile salt export pump ABCB11 (Bsep) involved in troglitazone-induced in…”
BackgroundThe Role of Drug Metabolism in Toxicity
Hanumegowda, U., & Davis, C. D. (2022) · Wiley eBooks · doi:10.1002/9781119851042.ch19 · Cited by 7
Jung, Y., & Kim, J. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c01094 · Cited by 7
Patel, N. N., Crincoli, C. M., Frederick, D. M., Tchao, R., & Harvison, P. J. (2011) · Journal of Applied Toxicology · doi:10.1002/jat.1639 · Cited by 7
“As noted above, TZD ring sulfoxidation has been proposed as a possible bioactivation mechanism for the glitazones (Kassahun et al., 2001; Tettey et al., 2001; He et al., 2004; Baughman et al., 2005).”
BackgroundAccessing, Using, and Creating Chemical Property Databases for Computational Toxicology Modeling
Williams, A. J., Ekins, S., Spjuth, O., & Willighagen, E. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-050-2_10 · Cited by 8
Patel, N. N., Crincoli, C. M., Kennedy, E. L., Frederick, D. M., Tchao, R., & Harvison, P. J. (2008) · Xenobiotica · doi:10.1080/00498250701830267 · Cited by 7
“Several studies have shown that metabolic activation, involving an initial cytochrome P450-mediated sulfoxidation step, can occur in the TZD ring of the glitazones (Kassahun et al. 2001; Tettey et al. 2001; He et al. 2004; Baughman et al. 2005; Alvárez-Sanchez et al. 2006), although whether this is a factor in hepatot…”
BackgroundUmemori, Y., Handa, K., Yoshimura, S., Kageyama, M., & Iijima, T. (2024) · Biomolecules · doi:10.3390/biom14050535 · Cited by 6
Current and Future Challenges for Collaborative Computational Technologies for the Life Sciences
Williams, A. J., Arnold, R. J. G., Neylon, C., Spencer, R. W., Schürer, S. C., & Ekins, S. (2011) · Wiley eBooks · doi:10.1002/9781118026038.ch28 · Cited by 7
Non-innocuous Consequences of Metabolic Oxidation of Alkyls on Arenes
Claesson, A., & Parkes, K. E. B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00833 · Cited by 6
Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes
Zhang, X., Zhu, B., Guo, L., Bakaj, I., Rankin, M. M., Ho, G., Kauffman, J. A., Lee, S. P., Norquay, L., & Macielag, M. J. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00667 · Cited by 6
Balls, M., Bogni, A., Bremer, S., Casati, S., Coecke, S., Eskes, C., Prieto, P., Sabbioni, E., Worth, A. P., Zuang, V., et al. (2002) · OpenAgrar · Cited by 6
Davies, G. F., Roesler, W. J., Ovsenek, N., & Bharadwaj, L. A. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00082-3 · Cited by 6
UCHIYAMA, M., Oguchi, M., Yamamura, N., Hiroko, K. O. D. A., FISCHER, T., Mueller, J., IZUMI, T., & Iwabuchi, H. (2010) · Journal of the Mass Spectrometry Society of Japan · doi:10.5702/massspec.58.1 · Cited by 6
▼Pioglitazone and ▼rosiglitazone for diabetes
(2001) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2001.39965 · Cited by 6
Zou, W., Roth, R. A., & Ganey, P. E. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm088 · Cited by 6
Bandookwala, M., Nemani, K. S., Chatterjee, B., & Sengupta, P. (2020) · Current Analytical Chemistry · doi:10.2174/1573411016666200131154202 · Cited by 5
Development of a cell viability assay to assess drug metabolite structure–toxicity relationships
Rana, P., Will, Y., Nadanaciva, S., & Jones, L. H. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.06.088 · Cited by 5
Kochansky, C. J., Rippley, R. K., Yan, K. X., Song, H., Wallace, M. A., Dean, D. C., Jones, A. N., Lasseter, K. C., Schwartz, J. I., Vincent, S. H., et al. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010231 · Cited by 5
“Interestingly, there have been several recent articles building on the work of Kassahun et al. (2001) with TZD-ring scission of troglitazone.”
BackgroundSelf-citationDrug Metabolism and Toxicity in Chimeric Mice with Humanized Liver
Emoto, C., Iwasaki, K., Murayama, N., & Yamazaki, H. (2011) · Eisei kagaku · doi:10.1248/jhs.57.22 · Cited by 5
Reactive Electrophiles and Metabolic Activation
Obach, R. S., & Kalgutkar, A. S. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00018-8 · Cited by 4
Improving Drug Design: Considerations for the Structural Modification Process
Nassar, A. F. (2010) · Wiley eBooks · doi:10.1002/9780470890387.ch4 · Cited by 4
Formation and Reactions of Xenobiotic Quinone Methides in Biology
Bolton, J. L., & Thompson, J. A. (2009) · Wiley eBooks · doi:10.1002/9780470452882.ch10 · Cited by 8
Uchiyama, M., Koda, H., Fischer, T., Mueller, J., Yamamura, N., Oguchi, M., Iwabuchi, H., Okazaki, O., & Izumi, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038729 · Cited by 4
“This oxidative TZD ring-opening pathway of troglitazone has been considered to be related to hepatotoxicity (Kassahun et al., 2001; Smith, 2003).”
BackgroundHosseini, A., Salman, M., Zhou, Z., Drackley, J. K., Trevisi, E., & Loor, J. J. (2017) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-017-0196-y · Cited by 4
“A study in mice reported that insulin-sensitizing compounds may act as antioxidants while increasing oxidative stress in the liver [42].”
Sato, T., Segawa, M., Sekine, S., & Ito, K. (2019) · The Journal of Toxicological Sciences · doi:10.2131/jts.44.811 · Cited by 4
“Troglitazone sulfate inhibits the bile salt export pump (BSEP), the major transporter of bile acid secretion from hepatocytes (Funk et al., 2001), and troglitazone quinone binds to intracellular macromolecules (Kassahun et al., 2001).”
Reactive Electrophiles and Metabolic Activation
Obach, R. S., & Kalgutkar, A. S. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64290-3 · Cited by 4
Features and Mechanisms of Drug‐Induced Liver Injury
Pessayre, D., Berson, A., & Fromenty, B. (2008) · Wiley eBooks · doi:10.1002/9780470372531.ch5 · Cited by 4
Drug Metabolism In Preclinical Development
Sinz, M. (2004) · Springer eBooks · doi:10.1007/978-1-4419-9216-1_4 · Cited by 5
Biotransformation and Rearrangement of Laromustine
Nassar, A. E. F., Wisnewski, A. V., & King, I. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.069823 · Cited by 4
“Stable isotope labeling provides great improvements and enhanced confidence in metabolite identification and characterization (Kassahun et al., 2001).”
BackgroundWang, J., Chen, L., & Mitra, K. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00112 · Cited by 3
Nassar, A. F. (2022) · Wiley eBooks · doi:10.1002/9781119851042.ch11 · Cited by 3
Alpha-hydroxybutyrate dehydrogenase and the diagnosis of painful crisis in sickle cell anaemia.
Akenzua, G. I., Ihongbe, J. C., & Asemota, H. N. (1992) · PubMed · Cited by 3
Cytochrome P450s: Drug–Drug Interactions
Rock, D. A., Wahlstrom, J. L., & Wienkers, L. C. (2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621460.ch9 · Cited by 3
Predicting Drug‐Induced Hepatotoxicity: In Vitro , In Silico and In Vivo Approaches
Xu, J. J., Kalgutkar, A. S. S., Will, Y., Dykens, J. A., Tengstrand, E., & Hsieh, F. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch15 · Cited by 3
Keerthi, K., Sivaramakrishnan, S., & Gates, K. S. (2008) · Chemical Research in Toxicology · doi:10.1021/tx8000187 · Cited by 3
Beconi, M. G., Mao, A., Creighton, M. D., Hop, C. E. C. A., Chiu, S. H. L., Eydelloth, R. S., Franklin, R. B., Tang, F. S., Yu, N. X., & Vincent, S. H. (2003) · Xenobiotica · doi:10.1080/0049825031000108333 · Cited by 3
Metabolism of troglitazone in hepatocytes isolated from experimentally induced diabetic rats
Meechan, A. J., Henderson, C. J., Bates, C. D., Grant, M. H., & Tettey, J. N. A. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.10.0009 · Cited by 5
“Also, TGZ and TGZQ are metabolized to GSH conjugates in the rat in-vivo (Kassahun et al 2001; Tettey et al 2001) and by in-vitro reactive metabolite trapping experiments using liver microsomes (He et al 2004).”
BackgroundMethodInfluentialThe Role of Drug Metabolism in Toxicity
Davis, C. D., & Hanumegowda, U. (2008) · Wiley eBooks · doi:10.1002/9780470439265.ch21 · Cited by 3
WANG, M., Wu, Y.-Q., Hwang, T., QIN, X., KARKI, S., & Treemaneekarn, V. (2004) · Journal of Chromatography B · doi:10.1016/s1570-0232(04)00622-1 · Cited by 3
Metabolic Activation-Role in Toxicity and Idiosyncratic Reactions
Walsh, J. S. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-44961-6_3 · Cited by 3
Characterization of Cytochrome P 450 Mechanism‐Based Inhibition
Rock, D. A., & Wienkers, L. C. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse117 · Cited by 3
Mallillin, M. C., Silva, D. A., Miller, N. A., Zhao, S., Salami, M., Löbenberg, R., & Davies, N. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070824 · Cited by 2
“…idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
Blass, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411508-8.00008-6 · Cited by 2
Chapter 2 Drug-Induced Hepatotoxicity: Learning from Recent Cases of Drug Attrition
Pähler, A., & Funk, C. (2008) · Advances in molecular toxicology · doi:10.1016/s1872-0854(07)02002-4 · Cited by 2
Hepatic Bioactivation and Drug-Induced Liver Injury
Kemper, R. A., & Lai, G. (2008) · Springer eBooks · doi:10.1007/978-0-387-77300-1_11 · Cited by 3
Metabolic Activation of Organic Functional Groups Utilized in Medicinal Chemistry
Kalgutkar, A. S. S. (2011) · Wiley eBooks · doi:10.1002/9780470929278.ch3 · Cited by 2
Ikeda, T. (2006) · Folia Pharmacologica Japonica · doi:10.1254/fpj.127.454 · Cited by 2
Ripp, S. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-77300-1_4 · Cited by 2
Bioactivation and Reactive Metabolite Assays
Tang, W., & Zhang, Z. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm113 · Cited by 2
Self-citationThe Role of Drug Metabolism in Toxicity
Davis, C. D., & Hanumegowda, U. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse120 · Cited by 2
Chapter 5 Idiosyncratic Drug Reactions: Clinical Evidence for Mechanistic Hypotheses
Uetrecht, J. (2006) · Advances in molecular toxicology · doi:10.1016/s1872-0854(06)01005-8 · Cited by 1
Molecular Interaction Fields for Predicting the Sites and Products of Metabolism
Broccatelli, F., & Brown, N. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673261.ch09 · Cited by 1
Kalgutkar, A. S. S. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511779053.008 · Cited by 1
Recent Findings Regarding the Mechanism of Idiosyncratic Drug Toxicity
Ikeda, T. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00249-1 · Cited by 1
Prediction of Drug Metabolism: Use of Structural Biology and In Silico Tools
Tyzack, J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00067-0 · Cited by 1
Characterization of Cytochrome P450 Mechanism Based Inhibition
Rock, D. A., & Wienkers, L. C. (2022) · Wiley eBooks · doi:10.1002/9781119851042.ch15 · Cited by 1
Idiosyncratic Drug Reactions and the Potential Role of Metabolism
Uetrecht, J. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm128 · Cited by 1
Wojcinski, Z. W., & Uetrecht, J. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm087 · Cited by 1
Bioactivation I: Bioactivation by Cytochrome P450s
Dalvie, D. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm072 · Cited by 1
Chemical Mechanisms in Toxicology
Grillo, M. P. (2008) · Wiley eBooks · doi:10.1002/9780470439265.ch23 · Cited by 1
Nassar, A. F. (2008) · Wiley eBooks · doi:10.1002/9780470439265.ch12 · Cited by 1
Role of Metabolism in Toxicity of Drugs in Humans
Kalgutkar, A. S. S., & Bauman, J. N. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm127
Coleman, M. D. (2010) · Wiley eBooks · doi:10.1002/9780470689332.furread
Dealing with Reactive Metabolite–Positive Compounds in Drug Discovery
Kalgutkar, A. S. S., Dalvie, D., Obach, R. S., & Smith, D. A. (2012) · Methods and principles in medicinal chemistry · doi:10.1002/9783527655748.ch14
Nassar, A. F. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse111
Chemical Mechanisms in Toxicology
Grillo, M. P. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse122
Role of Biotransformation in Drug Discovery
White, R. E. (2014) · Wiley eBooks · doi:10.1002/9781118541203.xen0007
Strategies for the Detection of Reactive Intermediates in Drug Discovery and Development
Grillo, M. P. (2010) · Wiley eBooks · doi:10.1002/9780470890387.ch7
Molecular Modelling Analysis of the Metabolism of Troglitazone
Huq, F. (2007) · Asian Journal of Biochemistry · doi:10.3923/ajb.2007.256.262
Development of a semi-automated covalent binding methodology
Nilsson, J. R. (2010) · Chalmers Publication Library (Chalmers University of Technology)
Molecular and pharmacological study of transcription factor Nrf2
Lin, W. (2009) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t34x5819 · Cited by 1
Vásquez, Y. (2016) · Cited by 1
Li, A. P. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch8
Anari, M. R., Tiller, P. R., & Baillie, T. A. (2005) · Progress in pharmaceutical and biomedical analysis · doi:10.1016/s1464-3456(05)80010-9
Self-citationSmith, D. A., Allerton, C. M. N., Kalgutkar, A. S. S., Waterbeemd, H. V. D., & Walker, D. K. (2012) · Methods and principles in medicinal chemistry · doi:10.1002/9783527645763.ch8
Blass, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817214-8.00008-7
Uetrecht, J. P., & Trager, W. F. (2007) · CRC Press eBooks · doi:10.1201/b14488-9
(2007) · CRC Press eBooks · doi:10.3109/9780849375965-9
(2002) · Alternatives to Laboratory Animals · doi:10.1177/026119290203001s07
Cytochrome P450 Activation of Toxins and Hepatotoxicity
Guengerich, F. P. (2007) · CRC Press eBooks · doi:10.3109/9781420021141-3 · Cited by 1
Characterization of Cytochrome P450 Mechanism‐Based Inhibition
Rock, D. A., & Wienkers, L. C. (2008) · Wiley eBooks · doi:10.1002/9780470439265.ch18
Metadata
- Authors
- Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kassahun, Kelem
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-12-08
- Volume
- 14
- Issue
- 1
- Pages
- 62-70
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2068532562
- Cited by
- 311
- References
- 8
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 9 · 2014: 15 · 2013: 12 · 2012: 16
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- troglitazone, drug metabolism, reactive metabolites, glutathione conjugates, CYP3A, hepatotoxicity, drug-induced liver injury, sulfenic acid, oxidative stress, redox cycling, covalent protein modification, human liver microsomes, bile
- MeSH terms
- Troglitazone, Animals, Bile, Biotransformation, Catalysis, Chromans, Chromatography, Liquid, Cytochrome P-450 Enzyme System, Glutathione, Humans, Hypoglycemic Agents, Isoenzymes, Ketoconazole, Kinetics, Microsomes, Liver, NADP, Mass Spectrometry, Steroid Hydroxylases, Thiazoles, Thiazolidinediones, Rats, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.